All In Biotech

Drug Trial Radar · NCT00519285

Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer

A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen-independent Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Jul 22, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,224 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,224

Actual

Start

Aug 2007

Primary completion

Apr 2012

Study completion Apr 2012

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Aug 22, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary objective was to demonstrate overall survival improvement with aflibercept compared to placebo in patients receiving docetaxel / prednisone for metastatic androgen-independent prostate cancer (MAIPC). The secondary objectives were: * To assess the efficacy of aflibercept compared to placebo on other parameters such prostate-specific antigen (PSA) level, cancer related pain, progression free survival (PFS), tumor-based and skeletal events and health-related quality of life (HRQL); * To assess the overall safety in both treatment arms; * To determine the pharmacokinetics of intravenous (IV) aflibercept in this population; * to determine immunogenicity of IV aflibercept.

Conditions

  • Prostatic Neoplasms
  • Neoplasm Metastasis

Interventions

  • AfliberceptDrug

    25 mg/ml solution 6 mg/kg, 1-hour IV on Day 1 of each 3-Week cycle

  • Placebo (for aflibercept)Drug

    Sterile aqueous buffered solution identical to aflibercept 1-hour IV on Day 1 of each 3-Week cycle

  • DocetaxelDrug

    Marketed formulation 75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)

  • Prednisone or PrednisoloneDrug

    Marketed formulation 5 mg twice daily PO from day 1 continuously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival TimeTime frame: From randomization up to the cut-off date (median follow-up of 35.4 months)

Locations

31 sites in 31 countries. Site status is shown where the registry gives one.

  • Sanofi-Aventis Administrative Office

    Bridgewater, New Jersey

  • Sanofi-Aventis Administrative Office

    Buenos Aires, Argentina

  • Sanofi-Aventis Administrative Office

    Macquarie Park, Australia

  • Sanofi-Aventis Administrative Office

    Diegem, Belgium

  • Sanofi-Aventis Administrative Office

    São Paulo, Brazil

  • Sanofi-Aventis Administrative Office

    Laval, Canada

  • Sanofi-Aventis Administrative Office

    Providencia Santiago, Chile

  • Sanofi-Aventis Administrative Office

    City of Zagreb, Croatia

  • Sanofi-Aventis Administrative Office

    Prague, Czechia

  • Sanofi-Aventis Administrative Office

    Hørsholm, Denmark

  • Sanofi-Aventis Administrative Office

    Tallinn, Estonia

  • Sanofi-Aventis Administrative Office

    Paris, France

  • Sanofi-Aventis Administrative Office

    Frankfurt, Germany

  • Sanofi-Aventis Administrative Office

    Hong Kong, Hong Kong

  • Sanofi-Aventis Administrative Office

    Budapest, Hungary

  • Sanofi-Aventis Administrative Office

    Netanya, Israel

  • Sanofi-Aventis Administrative Office

    Milan, Italy

  • Sanofi-Aventis Administrative Office

    Gouda, Netherlands

  • Sanofi-Aventis Administrative Office

    Warsaw, Poland

  • Sanofi-Aventis Administrative Office

    Porto Salvo, Portugal

  • Sanofi-Aventis Administrative Office

    Moscow, Russia

  • Sanofi-Aventis Administrative Office

    Singapore, Singapore

  • Sanofi-Aventis Administrative Office

    Gauteng, South Africa

  • Sanofi-Aventis Administrative Office

    Seoul, South Korea

  • Sanofi-Aventis Administrative Office

    Barcelona, Spain

  • Sanofi-Aventis Administrative Office

    Bromma, Sweden

  • Sanofi-Aventis Administrative Office

    Geneva, Switzerland

  • Sanofi-Aventis Administrative Office

    Taipei, Taiwan

  • Sanofi-Aventis Administrative Office

    Istanbul, Turkey (Türkiye)

  • Sanofi-Aventis Administrative Office

    Kiev, Ukraine

  • Sanofi-Aventis Administrative Office

    Guildford Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.